<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25454" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Myeloproliferative Neoplasms</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thapa</surname>
            <given-names>Bicky</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fazal</surname>
            <given-names>Salman</given-names>
          </name>
          <aff>Allegheny Health Network</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parsi</surname>
            <given-names>Meghana</given-names>
          </name>
          <aff>Crozer Chester Medical Center/ Drexel University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rogers</surname>
            <given-names>Heesun J.</given-names>
          </name>
          <aff>Cleveland Clinic</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Bicky Thapa declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Salman Fazal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Meghana Parsi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heesun Rogers declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25454.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Hematopoietic pluripotent stem cells have self-renewal capability and give rise to either myeloid or the lymphoid lineage which further differentiates into various mature blood cells such as red blood cells (RBC), lymphocytes, granulocytes, megakaryocytes, and macrophages. The hematopoietic process is determined by the bone marrow environment, growth factors, and transcription factors. The abnormal proliferation of one or more terminal myeloid cell lines in the peripheral blood gives rise to a heterogeneous group of disorders called myeloproliferative neoplasms. Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are four classic types of myeloproliferative neoplasms. This activity reviews the evaluation and management of myeloproliferative neoplasms and highlights the role of the interprofessional team in improving care for patients with these conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of myeloproliferative neoplasms.</p></list-item><list-item><p>Describe how to evaluate for myeloproliferative neoplasms.</p></list-item><list-item><p>Outline the treatment and management options available for myeloproliferative neoplasms.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination and communication to advance care and improve outcomes for patients with myeloproliferative neoplasms.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25454&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25454">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25454.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hematopoietic pluripotent stem cells have self-renewal capability and give rise to either myeloid or the lymphoid lineage which further differentiates into various mature blood cells such as red blood cells (RBC), lymphocytes, granulocytes, megakaryocytes, and macrophages. The hematopoietic process is determined by the bone marrow environment, growth factors, and transcription factors.</p>
        <p>The abnormal proliferation of one or more terminal myeloid cell lines in the peripheral blood gives rise to a heterogeneous group of disorders called myeloproliferative neoplasms. In 1951, William Dameshek coined the term <italic toggle="yes">myeloproliferative disorders</italic> which are now reformed to myeloproliferative neoplasms (MPNs) by the World Health Organization (WHO). Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and&#x000a0;primary myelofibrosis&#x000a0;(PMF) are four classic types of myeloproliferative neoplasms. WHO classification also included chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), and MPN, unclassifiable.<xref ref-type="bibr" rid="article-25454.r1">[1]</xref> Out of the classic types of&#x000a0;MPNs, CML is <italic toggle="yes">BCR-ABL1 </italic>positive, but PV, ET, and PMF are <italic toggle="yes">BCR-ABL1 </italic>negative. Besides, the fourth edition of WHO classification for myeloid and acute leukemia was revised in 2016 due to recent advances in hematology with the identification of molecular markers and prognostic markers, giving a better understanding of the molecular pathogenesis and genetics of the hematological malignancies.<xref ref-type="bibr" rid="article-25454.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-25454.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Exact etiology of&#x000a0;MPNs is not known; however, patients with a genetic mutation (<italic toggle="yes">Janus kinase 2</italic>) are associated with a higher risk of developing MPNs. In addition, exposure to a higher level of ionizing radiation and toxins such as benzene has been associated with an increase in the risk for development of MPNs.</p>
      </sec>
      <sec id="article-25454.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p><italic toggle="yes">Chronic myeloid leukemia</italic>: It comprises 0.5% of all new cancer cases in the United States. As per recent SEER (Surveillance, Epidemiology, and End Results) national cancer database from the US, CML is commonly diagnosed in older age groups, ranging from 65 to 74 years, and the median age of diagnosis is 65 years. It is more common in males, with an incidence rate of about 2.4 new cases per 100,000 versus 1.4 new cases per 100,000 in females. About 67.6% of patients have a 5-year survival rate,&#x000a0;and the median age of death is about 77 years.&#x000a0;</p>
        <p><italic toggle="yes">Polycythemia vera</italic>: The median age of diagnosis of PV is 60 years. It is more prevalent in males as compared to&#x000a0;females, with a male to female ratio of 1.8: 1. The estimated incidence of PV ranges from 0.4 to 2.8 per 100,000 per year.</p>
        <p><italic toggle="yes">Essential thrombocythemia</italic>: The median age for diagnosis of ET is 60 years. It is more common in females, with a male to female ratio of 1:2. The estimated incidence of ET ranges from 1 to 2.5/100,000/year, and incidence increases with increasing age.<xref ref-type="bibr" rid="article-25454.r3">[3]</xref>&#x000a0;</p>
        <p><italic toggle="yes">Primary myelofibrosis</italic>:&#x000a0; The median age at the diagnosis is 67 years. The incidence rate varies from 0.8 to 2.1/100,000/year.&#x000a0;</p>
        <p>Other MPNs such as CNL, CEL, and unclassified MPN are rare; exact incidence and prevalence are not known due to the rarity of the disorders.</p>
      </sec>
      <sec id="article-25454.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>In the last decade, the treatment paradigm has changed with the detection of new driver mutations and a better understanding of the molecular pathogenesis of the MPNs. Mutations are divided into &#x0201c;restricted&#x0201d; which are found only in MPNs and &#x0201c;unrestricted&#x0201d; which are also detected in other myeloid malignancies; these mutations in hematopoietic stem cells (HSC) result in the clonal expansion of all myeloid cells, B cell, and natural killer cells, leading to MPNs.<xref ref-type="bibr" rid="article-25454.r4">[4]</xref></p>
        <p>Cytogenetics of CML is characterized by a reciprocal translocation between long arms of chromosomes 22 and 9, leading to the shortening of the length of the chromosome 22, also known as Philadelphia chromosomes, which is diagnostic of CML. The translocation involves the fusion of breakpoint cluster gene (<italic toggle="yes">BCR</italic>) on chromosome 22 with oncogene Abelson murine leukemia virus (<italic toggle="yes">ABL</italic>) on the long arm of chromosome 9 resulting in <italic toggle="yes">BCR-ABL</italic> fusion gene. The tyrosine kinase activity of the&#x000a0;<italic toggle="yes">ABL</italic>&#x000a0;oncogene is further enhanced with the fusion of <italic toggle="yes">BCR</italic> gene due to an encoding of a chimeric protein from <italic toggle="yes">BCR-ABL</italic> fusion gene.<xref ref-type="bibr" rid="article-25454.r5">[5]</xref></p>
        <p>In <italic toggle="yes">BCR-ABL1</italic> negative MPNs, the restricted driver mutations are JAK2, myeloproliferative leukemia virus proto-oncogene <italic toggle="yes">(MPL), CALR, and CSF3R,&#x000a0;</italic>which encodes for various tyrosine kinases.&#x000a0;</p>
        <p>Janus kinase<italic toggle="yes"> (JAK) 2 </italic>gene mutation: <italic toggle="yes">J</italic>anus kinase gene is a type of&#x000a0;protein kinase that phosphorylates signal transducer and activator of transcription (STAT) in the JAK-STAT pathway, and activation of this pathway results in the pathogenesis of the MPNs.<xref ref-type="bibr" rid="article-25454.r6">[6]</xref>&#x000a0;The&#x000a0;<italic toggle="yes">JAK2</italic>&#x000a0;mutation is found in about 70% of MPNs. It is a somatic mutation that involves the substitution of valine to phenylalanine at codon 617 (<italic toggle="yes">JAK2 V617F</italic>) in the pseudokinase domain. The frequency of <italic toggle="yes">JAK2 V617F</italic> mutation is 95%&#x000a0;in patients with PV, about 50% to 70% in ET, and 40% to 50% in PMF, respectively.&#x000a0;</p>
        <p>In 5% of PV with <italic toggle="yes">JAK2 V617F</italic> negative individuals, <italic toggle="yes">JAK2 </italic>exon 12 mutation is found;&#x000a0;however, no such mutation was found in ET and PMF.<xref ref-type="bibr" rid="article-25454.r7">[7]</xref></p>
        <p><italic toggle="yes">MPL proto-oncogene mutation</italic>:&#x000a0; The <italic toggle="yes">MPL</italic> gene codes the thrombopoietin (TPO) receptor which regulates megakaryopoiesis through a JAK-STAT pathway. The most common somatic <italic toggle="yes">MPL</italic> mutations are <italic toggle="yes">MPL W515L</italic> and <italic toggle="yes">MPL W515K</italic> which cause spontaneous activation of the JAK-STAT pathway, resulting in abnormal hematopoietic cell proliferation.<xref ref-type="bibr" rid="article-25454.r8">[8]</xref>&#x000a0;These mutations are found in up to 6% of ET and up to 10% of PMF as per literature.<xref ref-type="bibr" rid="article-25454.r4">[4]</xref><xref ref-type="bibr" rid="article-25454.r9">[9]</xref>&#x000a0;Furthermore, this mutation will help categorize patients diagnosed with negative <italic toggle="yes">JAK2 V617F</italic> mutation and Philadelphia chromosome MPN. <italic toggle="yes">MPL</italic> mutations increase the risk of thrombotic complications as compared to <italic toggle="yes">JAK2&#x000a0;V617F</italic>&#x000a0;mutation patients and&#x000a0;are associated with low hemoglobin, low bone marrow (BM)&#x000a0;cellularity, high platelets, and high serum erythropoietin levels.<xref ref-type="bibr" rid="article-25454.r9">[9]</xref><xref ref-type="bibr" rid="article-25454.r10">[10]</xref>&#x000a0;</p>
        <p><italic toggle="yes">Calreticulin (CALR) gene mutation</italic>: The&#x000a0;<italic toggle="yes">CALR</italic>&#x000a0;gene is located in chromosome 19 (exon 9) which encodes calreticulin, a calcium-binding endoplasmic reticulum chaperone protein that regulates cellular proliferation, differentiation, and apoptosis; this protein also plays a&#x000a0;role in immune system function and wound healing. In 2013, the somatic mutation (usually frameshift mutation) of the&#x000a0;<italic toggle="yes">CALR&#x000a0;</italic>gene was discovered in patients with ET and PMF who were negative for <italic toggle="yes">JAK2</italic> and <italic toggle="yes">MPL</italic> mutation.<xref ref-type="bibr" rid="article-25454.r11">[11]</xref>&#x000a0;The<italic toggle="yes">&#x000a0;CALR&#x000a0;</italic>exon 9 mutations are found in approximately 50% to 75% of patients with ET and PMF.<xref ref-type="bibr" rid="article-25454.r12">[12]</xref></p>
        <p>About 10% to 15% of ET and PMF patients lack all three driver mutations (<italic toggle="yes">JAK2</italic> V617F, <italic toggle="yes">MPL</italic>
<italic toggle="yes">W515L/K</italic>, and <italic toggle="yes">CALR</italic> exon 9), which are also known as triple-negative MPN.</p>
        <p>Chronic neutrophilic leukemia (CNL) is one of the myeloproliferative neoplasms which is characterized by peripheral leukocytosis with neutrophilia, hypercellularity of the BM&#x000a0;with less than 5% myeloblasts, and normal neutrophil maturation. The <italic toggle="yes">JAK2</italic>
<italic toggle="yes">V617F</italic> mutation is common in CNL;&#x000a0;however, detection of mutation in colony-stimulating factor 3 receptor<italic toggle="yes"> (CSF3R) </italic>gene is one of the WHO diagnostic criteria for CNL and commonly occurs at a CSF3R T618I location in the gene.<xref ref-type="bibr" rid="article-25454.r13">[13]</xref></p>
      </sec>
      <sec id="article-25454.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>The peripheral blood (PB) and bone marrow (BM) findings of the different diseases are&#x000a0;as follows:</p>
        <p><italic toggle="yes">Chronic myeloid leukemia (CML)</italic>: The clinical course of the disease is divided into the chronic phase, accelerated phase, and blast crisis; histopathology varies with phases of the CML. Peripheral blood findings are positive for leukocytosis, with slight elevation of eosinophils, basophils, and monocytes. In patients with chronic phase, hypercellular bone marrow, myeloid hyperplasia with a left shift in maturation, and myeloblasts up to 10% are present. In accelerated phase, myeloblasts range from 10% to 19%, basophils 20% or higher, additional&#x000a0;clonal&#x000a0;chromosomal abnormality or other&#x000a0;diagnostic criteria should be presented, and in blast crisis, myeloblasts are greater than 20%, which is the transformation to acute myeloid leukemia.</p>
        <p><italic toggle="yes">Polycythemia vera (PV)</italic>:&#x000a0;PB in pre-polycythemic and overt polycythemic stage shows normochromic and normocytic RBCs, erythrocytosis with elevated hemoglobin (greater than 16.5 g/dL&#x000a0;in&#x000a0;male and 16.0 g/dL in female), leukocytosis, and thrombocytosis; however, in concomitant iron deficiency, PB shows a microcytic and hypochromic picture. In the post-polycythemic myelofibrosis stage, PB is characterized by leukoerythroblastosis, with teardrop-shaped RBCs and poikilocytosis. The BM findings in the pre-polycythemic and overt polycythemic stage are significant for hypercellularity and panmyelosis, with a variable proliferation of granulocyte precursors, erythroid cells, and megakaryocytes.</p>
        <p><italic toggle="yes">Essential thrombocythemia (ET)</italic>: PB findings are significant for thrombocytosis (450 X 10^9/L&#x000a0;or higher)&#x000a0;with platelet anisocytosis. In post-ET myelofibrosis, PB is notable for leukoerythroblastosis, with teardrop-shaped RBCs and poikilocytosis. The BM aspiration and biopsy show mild hypercellularity without any dyserythropoiesis, macrocytosis, and dysgranulopoiesis.</p>
        <p><italic toggle="yes">Primary myelofibrosis (PMF)</italic>: PB shows a leukoerythroblastic picture with immature granulocytes and nucleated RBC. The BM aspirate is usually a dry tap ("punctio sicca"), but biopsy is characterized by a&#x000a0;various&#x000a0;degree&#x000a0;of&#x000a0;fibrosis along with atypical morphology of megakaryocytes.</p>
        <p><italic toggle="yes">Chronic neutrophilic leukemia (CNL)</italic>: PB is characterized by leukocytosis (WBC 25 X 10^9/L) with segmented or band neutrophils (80% or higher), few neutrophil precursors (less than 10%), and rare myeloblasts. The BM aspirate and biopsy demonstrates hypercellularity and mature granulocytosis with normal maturation and no&#x000a0;dysgranulopoiesis.</p>
        <p><italic toggle="yes">Chronic eosinophilic leukemia (CEL)</italic>: Characterized by peripheral eosinophilia&#x000a0;(1,500/uL or higher), BM with elevated eosinophils,&#x000a0;myeloblasts less than 20% and a clonal&#x000a0;abnormality.</p>
      </sec>
      <sec id="article-25454.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Clinical manifestation of different myeloproliferative neoplasms are&#x000a0;as follows:</p>
        <p><italic toggle="yes">Chronic myeloid leukemia (CML)</italic>: Patient may be asymptomatic with an abnormal blood test, but common clinical manifestations include easy fatiguability, anorexia, weight loss, generalized malaise, sweating, abdominal discomfort or pain, abdominal fullness, early satiety, easy bruising, and bleeding. Physical examination may be positive for pallor, ecchymoses, and hepatosplenomegaly. In addition, priapism and sweet syndrome are rare findings.</p>
        <p><italic toggle="yes">Polycythemia vera (PV)</italic>: Patients with PV have increased red cell mass which contributes to hyperviscosity, hypoxia, and thrombosis. Clinical manifestations of PV include headache, dizziness, visual disturbances, pruritus, malaise, tinnitus, paresthesia, erythromelalgia, abdominal pain, loss of appetite, weight loss, bleeding, and symptoms related to thrombosis. Patients&#x000a0;often present&#x000a0;with aquagenic pruritus, which is itching/stinging or burning sensation after warm bath or shower. Physical findings may include hepato-splenomegaly, facial plethora, superficial thrombophlebitis, gouty arthritis, conjunctival injection, and hypertension.</p>
        <p><italic toggle="yes">Essential thrombocythemia (ET)</italic>: Clinical symptoms of ET varies from asymptomatic presentation to symptoms due to thrombosis, bleeding, and vasomotor symptoms. Common symptoms include a headache, dizziness, visual changes, paresthesia, fatigue, and easy bruising. Microvascular occlusions involving vessels of distal extremities may cause erythromelalgia and gangrene. A patient may present with stroke symptoms due to thromboembolic complications. Physical examination findings may include splenomegaly, which is more common than hepatomegaly.</p>
        <p><italic toggle="yes">Primary myelofibrosis (PMF)</italic>: The common symptoms include fatigue, night sweats, low-grade fever, early satiety, weight loss, abdominal fullness or discomfort, dysuria, hematuria, gastrointestinal (GI) bleeding, arthralgia, and bony pain. PMF is characterized by extramedullary hematopoiesis and BM fibrosis. Physical examination findings include pallor, petechiae, ecchymoses, splenomegaly, hepatomegaly, lymphadenopathy, pleural effusion, pericardial effusion, ascites, pulmonary edema, seizure, altered mental status, and spinal cord compression.&#x000a0;</p>
        <p><italic toggle="yes">Chronic neutrophilic leukemia (CNL)</italic>: Most patients are asymptomatic, but common symptoms on presentation include fatigue, night sweats, loss of appetite, weight loss, easy bruising, and bone pain. A patient may have splenomegaly at diagnosis on physical examination.</p>
      </sec>
      <sec id="article-25454.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The laboratory workup for the evaluation of MPNs includes&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Complete blood count with differential</p>
          </list-item>
          <list-item>
            <p>Peripheral blood&#x000a0;with microscopic examination</p>
          </list-item>
          <list-item>
            <p>Comprehensive metabolic panel</p>
          </list-item>
          <list-item>
            <p>Electrolytes</p>
          </list-item>
          <list-item>
            <p>Peripheral blood fluorescence in situ hybridization (FISH) or Reverse transcription-polymerase chain reaction (RT-PCR) for <italic toggle="yes">BCR-ABL1</italic></p>
          </list-item>
          <list-item>
            <p>Leukocyte alkaline phosphatase (LAP) score which helps to differentiate between reactive leukocytosis from CML. The LAP score is low in patients with CML and paroxysmal nocturnal hemoglobinuria, however, the score is high in leukemoid reaction.</p>
          </list-item>
          <list-item>
            <p>Serum uric acid</p>
          </list-item>
          <list-item>
            <p>Lactate dehydrogenase (LDH)</p>
          </list-item>
          <list-item>
            <p>Erythropoietin (EPO) level - normal or high in secondary polycythemia, but low or normal in PV.</p>
          </list-item>
          <list-item>
            <p>Von Willebrand factor - PV patients may develop acquired von Willebrand disease with platelet counts greater than 1 million/microL, and these patients are at increased risk of bleeding, particularly if they are on aspirin.</p>
          </list-item>
          <list-item>
            <p>Bone marrow aspiration and biopsy</p>
          </list-item>
          <list-item>
            <p>Cytogenetic analysis of the BM aspirate for <italic toggle="yes">Philadelphia Chromosome. FISH for bcr-abl.&#x000a0;</italic></p>
          </list-item>
          <list-item>
            <p>Peripheral blood molecular testing for&#x000a0;<italic toggle="yes">JAK2, MPL, CALR</italic>, and <italic toggle="yes">CSF3R </italic>mutations.</p>
          </list-item>
        </list>
        <p>Evaluation of MPNs involves comprehensive hematological/laboratory workup, BM biopsy, cytogenetic analysis, and clinical assessment. Owing to recent advances in molecular markers or driver mutations, 2008 WHO classification of myeloid neoplasm was updated in 2016 to incorporate new molecular biomarkers. Diagnostic criteria for MPNs based on revised and updated WHO classification are as follows<xref ref-type="bibr" rid="article-25454.r2">[2]</xref>:</p>
        <p>
<bold>WHO diagnostic criteria for CML (Accelerated and Blast Phase)</bold>
</p>
        <p>The diagnosis of the CML requires any one or more of the following for the accelerated phase:</p>
        <list list-type="bullet">
          <list-item>
            <p>Persistent or increasing WBC (greater than 10 X 10^9/L), Unresponsive to therapy</p>
          </list-item>
          <list-item>
            <p>Persistent thrombocytosis (greater than 1000 X 10^9/L), Unresponsive to therapy</p>
          </list-item>
          <list-item>
            <p>Persistent thrombocytopenia (greater than 100 X 10^9/L), Unrelated to therapy</p>
          </list-item>
          <list-item>
            <p>Persistent or increasing splenomegaly, Unresponsive to therapy</p>
          </list-item>
          <list-item>
            <p>Basophils greater than or equal to 20% in peripheral blood</p>
          </list-item>
          <list-item>
            <p>Blast cells 10% to 19% in peripheral blood or bone marrow</p>
          </list-item>
          <list-item>
            <p>Additional clonal chromosomal abnormality in Philadelphia positive cells at diagnosis</p>
          </list-item>
          <list-item>
            <p>Any new clonal chromosomal abnormality in Philadelphia positive cells during therapy</p>
          </list-item>
        </list>
        <p>The diagnosis criteria for CML (blast phase) includes any one&#x000a0;of the above criteria and blast cells greater than or equal to 20% in peripheral blood or BM or extramedullary involvement of lymph nodes, skin, lung, central nervous system, and bone.&#x000a0;</p>
        <p><bold>Revised WHO</bold>&#x000a0;<bold>Diagnostic Criteria for Polycythemia Vera</bold></p>
        <p>Diagnosis of PV necessitates the presence of&#x000a0;either all three major criteria or the first two major criteria and one minor criterion.</p>
        <p>
<bold>
<italic toggle="yes">Major criteria</italic>
</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Hemoglobin greater than 16.5 g/dL in male and hemoglobin greater than 16.0 g/dL in female ORHematocrit greater than 49% in male and hematocrit greater than 48% in female ORIncreased red cell mass greater than 25% above mean normal predicted value</p>
          </list-item>
          <list-item>
            <p>Bone marrow biopsy with trilineage myeloproliferation (panmyelosis) and hypercellularity for age</p>
          </list-item>
          <list-item>
            <p>Presence of <italic toggle="yes">JAK2 V617F</italic> or <italic toggle="yes">JAK</italic> exon 12 mutation</p>
          </list-item>
        </list>
        <p>
<bold>
<italic toggle="yes">Minor criterion</italic>
</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Serum erythropoietin below normal</p>
          </list-item>
        </list>
        <p>Of note, patients with PV who fulfill the diagnostic criteria should also be evaluated for secondary causes of polycythemia.</p>
        <p>
<bold>Revised WHO Diagnostic Criteria for&#x000a0;</bold>
<bold>Essential Thrombocythemia</bold>
</p>
        <p>Diagnosis of ET requires either the presence of&#x000a0;all four major criteria or the first three major criteria and the minor criterion.</p>
        <p>
<italic toggle="yes">
<bold>Major criteria</bold>
</italic>
</p>
        <list list-type="order">
          <list-item>
            <p>Platelet count greater than or equal to 450 X 10^9/L</p>
          </list-item>
          <list-item>
            <p>Bone marrow biopsy with a proliferation of megakaryocyte lineage with increased numbers of large, mature megakaryocytes. No increase in neutrophil granulopoiesis or erythropoiesis.</p>
          </list-item>
          <list-item>
            <p>Not meeting WHO criteria for <italic toggle="yes">BCR-ABL1</italic> positive CML, PMF, PV, MDS, or other myeloid neoplasms</p>
          </list-item>
          <list-item>
            <p>Detection of <italic toggle="yes">JAK2</italic>, <italic toggle="yes">CALR</italic>, or <italic toggle="yes">MPL</italic> mutation</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Minor criterion</bold>
</italic>
</p>
        <list list-type="order">
          <list-item>
            <p>Presence of clonal marker or absence of evidence for reactive thrombocytosis&#x000a0;</p>
          </list-item>
        </list>
        <p>
<bold>Revised WHO Diagnostic Criteria for Primary Myelofibrosis</bold>
</p>
        <p>The diagnosis of PMF requires the presence of&#x000a0;all three major criteria and at least one of the minor criteria.&#x000a0;</p>
        <p>
<italic toggle="yes">
<bold>Major criteria</bold>
</italic>
</p>
        <list list-type="order">
          <list-item>
            <p>Bone marrow findings of megakaryocyte proliferation with atypia, usually accompanied by reticulin and/or collagen fibrosis</p>
          </list-item>
          <list-item>
            <p>Not meeting the WHO criteria for <italic toggle="yes">BCR-ABL1</italic> positive CML, ET, PV, MDS, or other myeloid neoplasms</p>
          </list-item>
          <list-item>
            <p>Detection of <italic toggle="yes">JAK2</italic>, <italic toggle="yes">CALR</italic>, or <italic toggle="yes">MPL</italic> mutation or presence of clonal markers in the absence of these mutations</p>
          </list-item>
        </list>
        <p>
<italic toggle="yes">
<bold>Minor criteria</bold>
</italic>
</p>
        <list list-type="order">
          <list-item>
            <p>Anemia not attributed to another comorbid condition</p>
          </list-item>
          <list-item>
            <p>Leukocytosis greater than or equal to 11 X 10^9/L</p>
          </list-item>
          <list-item>
            <p>Palpable splenomegaly</p>
          </list-item>
          <list-item>
            <p>Elevated LDH</p>
          </list-item>
          <list-item>
            <p>Leukoerythroblastosis</p>
          </list-item>
        </list>
        <p>
<bold>Revised WHO diagnostic criteria for&#x000a0;Chronic Neutrophilic Leukemia</bold>
</p>
        <list list-type="order">
          <list-item>
            <p>Peripheral blood with WBC greater than or equal to 25 X 10^9/L, segmented neutrophils plus band forms greater than or equal to 80% of WBCs, neutrophil precursors less than 10%, rare myeloblasts, monocyte count less than 1 X 10^9/L, and no dysgranulopoiesis</p>
          </list-item>
          <list-item>
            <p>Bone marrow hypercellularity with elevated neutrophil granulocytes, normal neutrophil maturation, and myeloblast less than 5% of nucleated cells</p>
          </list-item>
          <list-item>
            <p>Not meeting WHO criteria for <italic toggle="yes">BCR-ABL1</italic> positive CML, ET, PV, or PMF</p>
          </list-item>
          <list-item>
            <p>No rearrangement of <italic toggle="yes">PDGFRA</italic>,<italic toggle="yes"> PDGFRB</italic>, or <italic toggle="yes">FGFR1</italic>, or <italic toggle="yes">PCM1-JAK2</italic></p>
          </list-item>
          <list-item>
            <p>Detection of <italic toggle="yes">CSF3R T618I</italic> or other activating <italic toggle="yes">CSF3R</italic> mutation or in the absence of a <italic toggle="yes">CSF3R&#x000a0;</italic>mutation sustained neutrophilia for at least 3 months, splenomegaly and no identifiable cause of reactive neutrophilia including an absence of a plasma cell neoplasm</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25454.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Management or treatment of the different MPNs are&#x000a0;as follows:</p>
        <p><italic toggle="yes">Chronic myeloid leukemia (CML)</italic>: Philadelphia chromosome is the <italic toggle="yes">BCR-ABL1 </italic>fusion gene which results in dysregulated tyrosine kinase activity. Tyrosine kinase inhibitors (TKI) targets tyrosine kinase activity of the <italic toggle="yes">BCR-ABL1 </italic>fusion gene. CML is divided into three phases: chronic phase accelerated phase and blast phase. Patients with chronic phase are managed initially with TKIs such as imatinib (first-generation TKIs) or nilotinib and dasatinib (second-generation TKIs). Based on ENESTND and DASISION, Nilotionib and Dasatinib respectively were superior to Imatinib in terms of achieving cytogenetic and molecular remission.&#x000a0; Patients in accelerated phase are treated with second-generation TKI and depending upon response may need hematopoietic stem cell transplantation (HCT). However blast phase CML patients undergo treatment with TKI and are evaluated for stem cell transplant.</p>
        <p><italic toggle="yes">Polycythemia vera (PV)</italic>: Patients are divided into high risk and low risk based on age and thrombotic events which also guide the management approach. Patient with age less than or equal to 60 years old with no history of a thrombotic event are classified as low-risk PV, however, patients with greater than 60 years or those who have a history of thrombotic events are considered high-risk patients. Low-risk PV is usually managed with low dose aspirin and therapeutic phlebotomy to maintain hematocrit less than 45%. High-risk PV is managed with therapeutic phlebotomy, low dose aspirin and the use of first-line cytoreductive agents such as hydroxyurea, busulfan, or interferon alfa. For those patients who do not respond to the first-line cytoreductive agents, ruxolitinib (tyrosine kinase inhibitor) as second-line therapy may be beneficial. Patients who develop acquired von Willebrand disease should avoid aspirin due to the increased risk of bleeding. Symptoms such as pruritus and erythromelalgia are generally well controlled with low dose aspirin, but recalcitrant cases may benefit from cytoreductive agents or ruxolitinib.</p>
        <p><italic toggle="yes">Essential thrombocythemia (ET)</italic>: The management of patients with ET is based on vasomotor symptoms, and it also involves the prevention of complications such as hemorrhage and thrombotic events. Vasomotor symptoms are usually controlled with low dose aspirin. Patients with high risk (age greater than 60 or thrombotic event at any age with positive <italic toggle="yes">JAK2 V617F</italic> mutation) or intermediate risk (age greater than 60, negative <italic toggle="yes">JAK2</italic> mutation, and no thrombotic event) are treated with a cytoreductive agent (hydroxyurea) and low dose aspirin. Very low or low risk includes patients 60 years or younger, with or without <italic toggle="yes">JAK2</italic> mutation and no thrombotic event; these patients are managed based on the symptoms with either low-dose aspirin or clinical monitoring alone.</p>
        <p><italic toggle="yes">Primary myelofibrosis (PMF)</italic>: Patients with Intermediate and high-risk disease with Myelofibrosis benefit from Ruxolitinib. Based on the COMFORT trials Ruxolitinib was helpful in reducing spleen volume and improving symptoms related to Myelofibrosis. Allogeneic hematopoietic cell transplantation is recommended in patients with the high-risk disease with the potential to cure. Asymptomatic, low-risk patients are managed with observation only.</p>
        <p><italic toggle="yes">Chronic neutrophilic leukemia (CNL)</italic>: Because of the rarity of the disease, there is no specific treatment. Most patients are managed with a cytoreductive agent (hydroxyurea).</p>
      </sec>
      <sec id="article-25454.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Chronic myelogenous leukemia</p>
          </list-item>
          <list-item>
            <p>Chronic lymphocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Chronic myelomonocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Juvenile myelomonocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Acute myeloid leukemia</p>
          </list-item>
          <list-item>
            <p>Acute lymphoblastic leukemia</p>
          </list-item>
          <list-item>
            <p>Leukemoid reactions/hyperleukocytosis</p>
          </list-item>
          <list-item>
            <p>Essential thrombocytosis</p>
          </list-item>
          <list-item>
            <p>Secondary thrombocytosis</p>
          </list-item>
          <list-item>
            <p>Juvenile myelomonocytic leukemia</p>
          </list-item>
          <list-item>
            <p>Mastocytosis</p>
          </list-item>
          <list-item>
            <p>Hypereosinophilic syndrome</p>
          </list-item>
          <list-item>
            <p>Primary myelofibrosis</p>
          </list-item>
          <list-item>
            <p>Non-Hodgkin lymphoma</p>
          </list-item>
          <list-item>
            <p>Myelodysplastic syndromes</p>
          </list-item>
          <list-item>
            <p>Multiple myelomas&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Splenomegaly</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25454.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>With the advent of&#x000a0;the tyrosine kinase inhibitors, the prognosis of the CML has significantly improved.</p>
        <p>Patients with ET usually have a good prognosis with normal life expectancy.</p>
        <p>Triple-negative PMF patients have been observed as a worse prognosis. Furthermore, Kampfl et al. reported better survival benefit in patients with <italic toggle="yes">CALR</italic> exon 9 mutations as compared to <italic toggle="yes">JAK2</italic> or <italic toggle="yes">MPL</italic> mutations.<xref ref-type="bibr" rid="article-25454.r11">[11]</xref>&#x000a0;</p>
        <p>Patients with PV who transform to MDS or AML have a very poor prognosis. As per one of the retrospective studies, older age (greater than 70 years), leukocytosis, and thrombosis are prognostic factors for worse survival in patients with PV.<xref ref-type="bibr" rid="article-25454.r14">[14]</xref></p>
      </sec>
      <sec id="article-25454.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Thrombosis and hemorrhagic events are the most common complications in MPNs.&#x000a0;Other complications based on diseases are&#x000a0;as follows:</p>
        <p><italic toggle="yes">Chronic myeloid leukemia (CML)</italic>: CML patients if not treated are at increased risk of blast transformation.</p>
        <p><italic toggle="yes">Polycythemia vera (PV)</italic>: Arterial and venous thrombosis and thromboembolic complications may manifest as transient ischemic stroke (TIA)/stroke and pulmonary embolism, myocardial infarction, and hemorrhage. Some patients with PV may present as acquired von Willebrand disease, and they have an increased tendency for bleeding,&#x000a0;particularly if they are taking aspirin. Post-PV myelofibrosis and transformation to AML or MDS are other complications of PV. Erythromelalgia is the microvascular complication of PV which manifest as pallor, erythema, or cyanosis of the hands and feet.</p>
        <p><italic toggle="yes">Essential thrombocythemia (ET)</italic>: Small and large vessel thrombosis, hemorrhage, thromboembolic complications such as stroke, pulmonary embolism, myocardial infarction, pulmonary hypertension, and priapism.</p>
        <p><italic toggle="yes">Primary myelofibrosis (PMF)</italic>: Portal hypertension, GI bleeding, spinal cord compression, bleeding, respiratory distress, transformation to acute leukemia, thrombotic events,&#x000a0; infections, and pulmonary hypertension.</p>
      </sec>
      <sec id="article-25454.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Myeloproliferative neoplasms are challenging to diagnose and treat. In order to provide the best care of patients afflicted with these neoplasms, due to the complexity of care and follow up required, a multiple disciplinary team should be involved consisting of specialty trained oncology nurses, oncologists, pharmacists, and additional support staff to assist with family and patient education. This will produce the best outcomes. [Level V]</p>
      </sec>
      <sec id="article-25454.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25454&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25454">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/myeloproliferative-neoplasms/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=25454">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25454/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25454">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25454.s15">
        <title>References</title>
        <ref id="article-25454.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vardiman</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.</article-title>
            <source>Cancer</source>
            <year>2009</year>
            <month>Sep</month>
            <day>01</day>
            <volume>115</volume>
            <issue>17</issue>
            <fpage>3842</fpage>
            <page-range>3842-7</page-range>
            <pub-id pub-id-type="pmid">19472396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arber</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Orazi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hasserjian</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Borowitz</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Le Beau</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bloomfield</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vardiman</surname>
                <given-names>JW</given-names>
              </name>
            </person-group>
            <article-title>The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.</article-title>
            <source>Blood</source>
            <year>2016</year>
            <month>May</month>
            <day>19</day>
            <volume>127</volume>
            <issue>20</issue>
            <fpage>2391</fpage>
            <page-range>2391-405</page-range>
            <pub-id pub-id-type="pmid">27069254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srour</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Devesa</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Check</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Curtis</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Linet</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Dores</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.</article-title>
            <source>Br J Haematol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>174</volume>
            <issue>3</issue>
            <fpage>382</fpage>
            <page-range>382-96</page-range>
            <pub-id pub-id-type="pmid">27061824</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vainchenker</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kralovics</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.</article-title>
            <source>Blood</source>
            <year>2017</year>
            <month>Feb</month>
            <day>09</day>
            <volume>129</volume>
            <issue>6</issue>
            <fpage>667</fpage>
            <page-range>667-679</page-range>
            <pub-id pub-id-type="pmid">28028029</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Faderl</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Talpaz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Estrov</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurzrock</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kantarjian</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>The biology of chronic myeloid leukemia.</article-title>
            <source>N Engl J Med</source>
            <year>1999</year>
            <month>Jul</month>
            <day>15</day>
            <volume>341</volume>
            <issue>3</issue>
            <fpage>164</fpage>
            <page-range>164-72</page-range>
            <pub-id pub-id-type="pmid">10403855</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saeidi</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Myeloproliferative neoplasms: Current molecular biology and genetics.</article-title>
            <source>Crit Rev Oncol Hematol</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>98</volume>
            <fpage>375</fpage>
            <page-range>375-89</page-range>
            <pub-id pub-id-type="pmid">26697989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Tong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Beer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Stratton</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Futreal</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Erber</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>McMullin</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Warren</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Gilliland</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Lodish</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.</article-title>
            <source>N Engl J Med</source>
            <year>2007</year>
            <month>Feb</month>
            <day>01</day>
            <volume>356</volume>
            <issue>5</issue>
            <fpage>459</fpage>
            <page-range>459-68</page-range>
            <pub-id pub-id-type="pmid">17267906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pikman</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Mercher</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>McDowell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ebert</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Gozo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cuker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wernig</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Galinsky</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>DeAngelo</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Golub</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Wadleigh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gilliland</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>RL</given-names>
              </name>
            </person-group>
            <article-title>MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.</article-title>
            <source>PLoS Med</source>
            <year>2006</year>
            <month>Jul</month>
            <volume>3</volume>
            <issue>7</issue>
            <fpage>e270</fpage>
            <pub-id pub-id-type="pmid">16834459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Akp&#x00131;nar</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Han&#x000e7;er</surname>
                <given-names>VS</given-names>
              </name>
              <name>
                <surname>Nal&#x000e7;ac&#x00131;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Diz-K&#x000fc;&#x000e7;&#x000fc;kkaya</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>MPL W515L/K Mutations in Chronic Myeloproliferative Neoplasms.</article-title>
            <source>Turk J Haematol</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-12</page-range>
            <pub-id pub-id-type="pmid">24385746</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Beer</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Bench</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Erber</surname>
                <given-names>WN</given-names>
              </name>
              <name>
                <surname>Bareford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wilkins</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Reilly</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Hasselbalch</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Bowman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wheatley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Buck</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.</article-title>
            <source>Blood</source>
            <year>2008</year>
            <month>Jul</month>
            <day>01</day>
            <volume>112</volume>
            <issue>1</issue>
            <fpage>141</fpage>
            <page-range>141-9</page-range>
            <pub-id pub-id-type="pmid">18451306</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klampfl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gisslinger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Harutyunyan</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Nivarthi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Rumi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Milosevic</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Them</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Berg</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Gisslinger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pietra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vladimer</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Bagienski</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Milanesi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Casetti</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Sant'Antonio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ferretti</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Elena</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schischlik</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Six</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schalling</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;negger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bock</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Malcovati</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pascutto</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Superti-Furga</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kralovics</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Somatic mutations of calreticulin in myeloproliferative neoplasms.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Dec</month>
            <day>19</day>
            <volume>369</volume>
            <issue>25</issue>
            <fpage>2379</fpage>
            <page-range>2379-90</page-range>
            <pub-id pub-id-type="pmid">24325356</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nangalia</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Massie</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Baxter</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Nice</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Gundem</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wedge</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Avezov</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kollmann</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Godfrey</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Hinton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martincorena</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Van Loo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Guglielmelli</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tarpey</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Harding</surname>
                <given-names>HP</given-names>
              </name>
              <name>
                <surname>Fitzpatrick</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Goudie</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Ortmann</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Loughran</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Raine</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Teague</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>O'Meara</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McLaren</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Silber</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dimitropoulou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bloxham</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mudie</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Maddison</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Keohane</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maclean</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Orchard</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tauro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Du</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Greaves</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bowen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huntly</surname>
                <given-names>BJP</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Cross</surname>
                <given-names>NCP</given-names>
              </name>
              <name>
                <surname>Ron</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vannucchi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Papaemmanuil</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Campbell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>AR</given-names>
              </name>
            </person-group>
            <article-title>Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.</article-title>
            <source>N Engl J Med</source>
            <year>2013</year>
            <month>Dec</month>
            <day>19</day>
            <volume>369</volume>
            <issue>25</issue>
            <fpage>2391</fpage>
            <page-range>2391-2405</page-range>
            <pub-id pub-id-type="pmid">24325359</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elliott</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chronic neutrophilic leukemia 2016: Update on diagnosis, molecular genetics, prognosis, and management.</article-title>
            <source>Am J Hematol</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>91</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-9</page-range>
            <pub-id pub-id-type="pmid">26700908</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25454.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tefferi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rumi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Finazzi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gisslinger</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Vannucchi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Rodeghiero</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Randi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Vaidya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cazzola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rambaldi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gisslinger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pieri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ruggeri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bertozzi</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Sulai</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Casetti</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Carobbio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jeryczynski</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larson</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>M&#x000fc;llauer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pardanani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thiele</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Passamonti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barbui</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.</article-title>
            <source>Leukemia</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>27</volume>
            <issue>9</issue>
            <fpage>1874</fpage>
            <page-range>1874-81</page-range>
            <pub-id pub-id-type="pmid">23739289</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
